The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: A retrospective follow-up study [4]

Journal of Clinical Psychopharmacology

Volumn 25, Issue 2, 2005, Pages 188-191

  Mulder, Hans ^a,b   Wilmink, Frederik W ^c   Beumer, Tim L ^d   Tamminga, Wim J ^d   Jedema, Jaap N ^b   Egberts, Antoine C G ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Wilhelmina Ziekenhuis   (Netherlands)

^c Psychiatric Hospital GGZ Drenthe   (Netherlands)

^d PRA International USA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450 2D6; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; MIANSERIN; NEUROLEPTIC AGENT; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; VENLAFAXINE; ZUCLOPENTHIXOL;

CONFIDENCE INTERVAL; DOSE RESPONSE; FOLLOW UP; GENE AMPLIFICATION; GENE DUPLICATION; GENETIC POLYMORPHISM; GENOTYPE; HAZARD ASSESSMENT; HOSPITALIZATION; HUMAN; LETTER; MEDICAL ETHICS; MENTAL DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; TREATMENT FAILURE;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HOSPITALIZATION; HOSPITALS, PSYCHIATRIC; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 15444378796     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000155832.79777.b5     Document Type: Letter

References (12)

1. Hirschfeld RMA, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63:826-837.
2. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry. 2000;61(suppl 2):10-12.
3. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356:1667-1671.
4. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol. 1999;55:177-184.
5. Tamminga WJ, Wemer J, Oosterhuis B, et al. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol. 2001;57:717-722.
6. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30-34.
7. Weiden PJ, Aquila R, Dalheim L, et al. Switching antipsychotic medications. J Clin Psychiatry. 1997;58(suppl 10):63-72.
8. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578-584.
9. Stüven T, Griese EU, Kroemer HK, et al. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reactions. Pharmacogenetics. 1996;6:417-421.
10. Clayton D, Hills M. Statistical Models in Epidemiology. New York: Oxford University Press; 1995.
11. Schillevoort I, Boer de A, Weide van der J, et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450-2D6 genotype. Pharmacogenetics. 2002;12:235-240.
12. Chou WH, Yan FX, Leon de J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20:246-251.